15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English 产妇和婴儿骨密度在分娩后1年在母亲替诺福韦地索普西富 ...
查看: 461|回复: 0
go

产妇和婴儿骨密度在分娩后1年在母亲替诺福韦地索普西富马 [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2019-4-3 15:45 |只看该作者 |倒序浏览 |打印
Clin Infect Dis. 2019 Mar 29. pii: ciy982. doi: 10.1093/cid/ciy982. [Epub ahead of print]
Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.
Salvadori N1,2, Fan B3, Teeyasoontranon W4, Ngo-Giang-Huong N1,2,5, Phanomcheong S6, Luvira A7, Puangsombat A8, Suwannarat A9, Srirompotong U10, Putiyanun C11, Cressey TR1,2,5,12, Decker L1,2, Khamduang W2, Harrison L13, Tierney C13, Shepherd JA3,14, Kourtis AP15, Bulterys M15,16, Siberry GK17, Jourdain G1,2,5.
Author information
Abstract

In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
KEYWORDS:

bone mineral density; growth; hepatitis B; pregnancy; tenofovir disoproxil fumarate

PMID:
    30924492
DOI:
    10.1093/cid/ciy982

Clin Infect Dis。 2019年3月29日.pii:ciy982。 doi:10.1093 / cid / ciy982。 [印刷前的电子版]
产妇和婴儿骨密度在分娩后1年在母亲替诺福韦地索普西富马酸盐的随机对照试验中预防母婴传播乙型肝炎病毒。
Salvadori N1,2,Fan B3,Teeyasoontranon W4,Ngo-Giang-Huong N1,2,5,Phanomcheong S6,Luvira A7,Puangsombat A8,Suwannarat A9,Srirompotong U10,Putiyanun C11,Cressey TR1,2,5,12,Decker L1,2,Khamduang W2,Harrison L13,Tierney C13,Shepherd JA3,14,Kourtis AP15,Bulterys M15,16,Siberry GK17,Jourdain G1,2,5。
作者信息
抽象

在一项随机,双盲,安慰剂对照试验中,使用替诺福韦地索普西富马酸盐(TDF)从产后28周至产后2个月预防母婴传播乙型肝炎病毒,产妇TDF没有显着影响分娩/分娩后1年使用母体或婴儿骨密度。临床试验注册。 NCT01745822。

©The Author(s)2019。由牛津大学出版社出版,为美国传染病学会。版权所有。对于权限,请发送电子邮件至:[email protected]
关键词:

骨密度;增长;乙型肝炎;怀孕;替诺福韦地索普西富马酸盐

结论:
    30924492
DOI:
    10.1093 / CID / ciy982
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-15 23:41 , Processed in 0.013257 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.